

UnitedHealthcare Community Plan Medical Policy Update Bulletin Quick View: June 2025



A list of recently approved, revised, and/or retired Medical Policies and/or Medical Benefit Drug Policies is provided below for your reference. **For a comprehensive summary of the latest updates, refer to the [Medical Policy Update Bulletin: June 2025](#).**

Medical Policy Updates

| Policy Title | Status | Effective Date |
|--|---------|----------------|
| Breast Reduction Surgery | Updated | Jun. 1, 2025 |
| Cell-Free Fetal DNA Testing | Revised | Aug. 1, 2025 |
| Chelation Therapy | Revised | Aug. 1, 2025 |
| Epidural Steroid Injections for Spinal Pain | Revised | Aug. 1, 2025 |
| Gynecomastia Surgery | Revised | Aug. 1, 2025 |
| Home Health, Skilled, and Custodial Care Services | Updated | Aug. 1, 2025 |
| Lithotripsy for Salivary Stones | Retired | Jun. 1, 2025 |
| Mechanical Stretching Devices | Updated | Jun. 1, 2025 |
| Proton Beam Radiation Therapy | Revised | Aug. 1, 2025 |
| Surgery of the Knee | Updated | Jun. 1, 2025 |
| Surgical and Ablative Procedures for Venous Insufficiency and Varicose Veins | Revised | Aug. 1, 2025 |
| Unicondylar Spacer Devices for Treatment of Pain or Disability | Retired | Jun. 1, 2025 |
| Upper Extremity Prosthetic Devices | Revised | Jun. 1, 2025 |

Medical Benefit Drug Policy Updates

| Policy Title | Status | Effective Date |
|---|---------|----------------|
| Amondys 45 [®] (Casimersen) | Revised | Jul. 1, 2025 |
| Entyvio [®] (Vedolizumab) | Revised | Jul. 1, 2025 |
| Exondys 51 [®] (Eteplirsen) | Revised | Jul. 1, 2025 |
| Ilumya [®] (Tildrakizumab-Asmn) | Updated | Jun. 1, 2025 |
| Immune Globulin (IVIG and SCIG) | Revised | Jul. 1, 2025 |
| Intravenous Enzyme Replacement Therapy (ERT) for Gaucher Disease | Revised | Jul. 1, 2025 |
| Ketalar [®] (Ketamine) and Spravato [®] (Esketamine) | Revised | Jun. 1, 2025 |
| Maximum Dosage and Frequency | Revised | Jul. 1, 2025 |
| Medical Therapies for Enzyme Deficiencies | Revised | Jun. 1, 2025 |
| Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease | Revised | Jul. 1, 2025 |
| Niktimvo [™] (Axatilimab-Csfr) | Updated | Jun. 1, 2025 |
| Oncology Medication Clinical Coverage | Revised | Jul. 1, 2025 |
| Ophthalmologic Vascular Endothelial Growth Factor (VEGF) Inhibitors | Revised | Jul. 1, 2025 |

| Policy Title | Status | Effective Date |
|---|---------------|-----------------------|
| Orencia® (Abatacept) Injection for Intravenous Infusion | Revised | Jun. 1, 2025 |
| Oxlumo® (Lumasiran) and Rivfloza® (Nedosiran) | Revised | Jul. 1, 2025 |
| Qalsody® (Tofersen) | Revised | Jun. 1, 2025 |
| Reblozyl® (Luspatercept-Aamt) | Revised | Jun. 1, 2025 |
| RNA-Targeted Therapies (Amvuttra® and Onpattro®) | Revised | Jul. 1, 2025 |
| Spevigo® (Spesolimab-Sbzo) | Revised | Jul. 1, 2025 |
| Testosterone Replacement or Supplementation Therapy | Revised | Jul. 1, 2025 |
| Veopoz® (Pozelimab-Bbfg) | Revised | Jun. 1, 2025 |
| Viltepso® (Viltolarsen) | Revised | Jul. 1, 2025 |
| Vyondys 53® (Golodirsen) | Revised | Jul. 1, 2025 |
| Zulresso® (Brexanolone) | Retired | Jun. 1, 2025 |

General Information

The inclusion of a health service (e.g., test, drug, device, or procedure) in this bulletin indicates only that UnitedHealthcare is adopting a new policy and/or updated, revised, replaced, or retired an existing policy; it does not imply that UnitedHealthcare provides coverage for the health service. Note that most benefit plan documents exclude from benefit coverage health services identified as investigational or unproven/not medically necessary. Physicians and other health care professionals may not seek or collect payment from a member for services not covered by the applicable benefit plan unless first obtaining the member's written consent, acknowledging that the service is not covered by the benefit plan and that they will be billed directly for the service.

Note: The absence of a policy does not automatically indicate or imply coverage. As always, coverage for a health service must be determined in accordance with the member's benefit plan and any applicable federal or state regulatory requirements. Additionally, UnitedHealthcare reserves the right to review the clinical evidence supporting the safety and effectiveness of a medical technology prior to rendering a coverage determination.

UnitedHealthcare respects the expertise of the physicians, health care professionals, and their staff who participate in our network. Our goal is to support you and your patients in making the most informed decisions regarding the choice of quality and cost-effective care, and to support practice staff with a simple and predictable administrative experience. The Medical Policy Update Bulletin was developed to share important information regarding changes to our Community Plan Medical Policies and Medical Benefit Drug Policies. When information in this bulletin conflicts with applicable state and/or federal law, UnitedHealthcare follows such applicable federal and/or state law.

Policy Update Classifications

New

New clinical coverage criteria have been adopted for a health service (e.g., test, drug, device, or procedure)

Updated

An existing policy has been reviewed and changes have not been made to the clinical coverage criteria; however, items such as the clinical evidence, FDA information, and/or list(s) of applicable codes may have been updated

Revised

An existing policy has been reviewed and revisions have been made to the clinical coverage criteria

Replaced

An existing policy has been replaced with a new or different policy

Retired

The health service(s) addressed in the policy are no longer being managed or are considered to be proven/medically necessary and are therefore not excluded as unproven/not medically necessary services, unless coverage guidelines or criteria are otherwise documented in another policy



The complete library of UnitedHealthcare Community Plan Medical Policies and Medical Benefit Drug Policies is available at [UHCprovider.com](https://www.uhcprovider.com) > Policies and Protocols > Community Plan Policies > Medical & Drug Policies.